Agilent Technologies (NYSE:A) had its price objective dropped by research analysts at Cfra from $89.00 to $85.00 in a research note issued on Friday, BenzingaRatingsTable reports. The brokerage currently has a "hold" rating on the medical research company's stock. Cfra's price objective points to a potential downside of 0.06% from the company's previous close.
A has been the topic of several other research reports. HSBC upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Wednesday, February 12th. Royal Bank of Canada assumed coverage on shares of Agilent Technologies in a research report on Tuesday, April 28th. They set a "sector perform" rating on the stock. UBS Group raised their price objective on shares of Agilent Technologies from $84.00 to $87.00 and gave the company a "neutral" rating in a research report on Friday. Piper Sandler raised their price objective on shares of Agilent Technologies from $86.00 to $96.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Finally, SunTrust Banks lowered their price objective on shares of Agilent Technologies from $90.00 to $75.00 and set a "hold" rating on the stock in a research report on Thursday, April 16th. Eleven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of "Hold" and a consensus target price of $85.75.
NYSE A traded up $4.30 on Friday, hitting $85.05. The stock had a trading volume of 306,475 shares, compared to its average volume of 2,093,521. Agilent Technologies has a 52-week low of $61.13 and a 52-week high of $90.64. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.27 and a current ratio of 1.64. The company has a market capitalization of $25.30 billion, a price-to-earnings ratio of 35.03 and a beta of 1.10. The firm has a 50-day moving average of $77.14 and a 200-day moving average of $79.93.
Agilent Technologies (NYSE:A) last posted its earnings results on Thursday, May 21st. The medical research company reported $0.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.61 by $0.10. Agilent Technologies had a net margin of 14.59% and a return on equity of 20.49%. The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the prior year, the company posted $0.71 EPS. The business's revenue for the quarter was up .2% compared to the same quarter last year. As a group, research analysts anticipate that Agilent Technologies will post 2.95 earnings per share for the current fiscal year.
In other Agilent Technologies news, VP Mark Doak sold 3,494 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $83.81, for a total value of $292,832.14. Following the completion of the sale, the vice president now owns 135,678 shares in the company, valued at approximately $11,371,173.18. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael R. Mcmullen sold 8,814 shares of Agilent Technologies stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $76.20, for a total value of $671,626.80. Following the completion of the sale, the chief executive officer now owns 542,848 shares in the company, valued at $41,365,017.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,929 shares of company stock worth $3,476,727.
A number of large investors have recently added to or reduced their stakes in A. BlackRock Inc. boosted its position in Agilent Technologies by 0.7% during the 1st quarter. BlackRock Inc. now owns 25,059,203 shares of the medical research company's stock valued at $1,794,739,000 after acquiring an additional 184,846 shares in the last quarter. State Street Corp raised its position in shares of Agilent Technologies by 0.4% in the 1st quarter. State Street Corp now owns 13,574,513 shares of the medical research company's stock worth $974,623,000 after acquiring an additional 50,304 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Agilent Technologies by 7.6% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,716,098 shares of the medical research company's stock valued at $487,640,000 after purchasing an additional 402,021 shares during the period. Invesco Ltd. boosted its position in shares of Agilent Technologies by 4.8% during the first quarter. Invesco Ltd. now owns 5,018,454 shares of the medical research company's stock valued at $359,422,000 after purchasing an additional 228,244 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Agilent Technologies by 2.0% during the first quarter. Geode Capital Management LLC now owns 4,950,997 shares of the medical research company's stock valued at $353,910,000 after purchasing an additional 95,831 shares in the last quarter.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Read More: Analyst Ratings
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Retail Stocks to Own For the Long Haul
There are more than 500 national retailers traded on the NYSE and the NASDAQ. Given the sheer number of big box stores, warehouse clubs, restaurant chains and other retail stores listed on public markets, it can be hard to identify which retailers are going to outperform the market.
Fortunately, some of Wall Street's top analysts have already done most of the work for us.
Every year, analyst issue approximately 4,200 distinct recommendations for retail companies. Analysts may not always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same retailer.
This slide show lists the 8 retail companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "8 Retail Stocks to Own For the Long Haul".